Agenda
- Welcome, Introduction, and Baseline Assessment
- Individualizing Treatment in Prostate Cancer
- Integrating Patient Preferences
- Clinical Pearls/Applications: Prostate Cancer Care and Evolution
- Closing Remarks and Audience Question and Answer Session
Events
Date / Time
Event Details
Faculty
Program Chair
Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology
Director, Prostate and GU Medical Oncology
Co-Director, Cancer Signaling Network Program
Yale Cancer Center
New Haven, Connecticut
Program Chair
David VanderWeele, MD, PhD
Associate Professor
Hematology/Oncology
Northwestern University
Attending Physician
Hematology/Oncology
Northwestern Medicine
Chicago, Illinois
Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and performance in applying practice-changing clinical data and expert recommendations to integrate the use of currently available therapies for their patients with metastatic prostate cancer.
Target Audience
This program is intended for oncologists, nurses, pharmacists, and other healthcare professionals on the multidisciplinary team caring for patients with prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate novel therapeutically actionable molecular targets that hold promise as predictive or prognostic biomarkers for patients with metastatic prostate cancer
- Plan optimal, individualized sequential therapeutic strategies for metastatic prostate cancer, considering all available agents, clinical data including novel imaging techniques, and expert recommendations
- Counsel patients with metastatic prostate cancer on available therapies, taking into consideration patient preferences regarding differences in administration and safety profiles, as well as comorbidities and patient goals
- Identify patients with metastatic prostate cancer who may be eligible for enrollment on ongoing clinical studies investigating novel regimens
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-022-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.